| Business Summary | | Genomica
Corp.
is
a
provider
of
software
products
and
services
that
are
designed
to
enable
pharmaceutical
and
biotechnology
researchers
to
accelerate
the
drug
discovery
and
development
process.
Discovery
Manager,
the
Company's
first
product,
is
used
for
genomics
research,
including
genetic
research,
gene
discovery
and
pharmacogenomics.
This
product
allows
researchers
to
turn
the
vast
volumes
of
gene,
SNP,
protein
and
patient
data
from
diverse
sources
into
information
useful
for
drug
discovery.
The
Company
licenses
Discovery
Manager
to
genomics-based
research
organizations,
including
AstraZeneca,
GlaxoSmithKline,
Pfizer,
National
Institutes
of
Health,
University
of
Oxford
and
the
National
Cancer
Institute. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genomica
Corp.
is
a
provider
of
software
products
and
services
that
are
designed
to
enable
pharmaceutical
and
biotechnology
researchers
to
accelerate
the
drug
discovery
and
development
process.
For
the
six
months
ended
6/30/01,
total
revenue
rose
18%
to
$907
thousand.
Net
loss
applicable
to
Common
decreased
61%
to
$11.1
million.
Results
reflect
licensing
fess
from
the
LinkMapper
product,
consulting
fees
from
Applied
Biosystems
and
the
absence
of
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Rathmann, 49 Chairman | -- | -- | Teresa Ayers, 48 CEO,
Director | $292K | $5.8M | Thomas Marr, Ph.D., 49 Pres,
Chief Scientist | 270K | 2.4M | Daniel Hudspeth, 38 CFO,
VP-Fin., Treasurer, Sec. | 175K | 2.6M | Kenneth Rubin, 36 Exec.
VP of Commercial Devel. | 243K | 409K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|